CollPlant’s investment story is built on the versatility of its plant-based technology, rhCollagen, and its application in regenerative medicine. It has strong potential across various subsectors, initially focusing on orthobiologics and advanced wound care. Two products have recently been launched: VergenixFG, targeting chronic and acute wounds, and VergenixSTR, targeting tendinopathy. CollPlant has recently postponed its NASDAQ offering and raised c $2m on TASE. Our rNPV prior the funding requirement is $61m (NIS225m), or 48c (NIS1.77) per share.

Continue reading

This version is programmatically created by Research Central and qualified in its entirety to the original PDF.

Powered by Research Central